GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Design
Randomized trial · 9650 participants · Hard outcome
Match to healthy normal-weight adults aged 55–75
Different populationType 2 diabetes with established vascular or kidney disease.
Could weight loss explain it?
Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
Study tier
Study tier 1[Auto] Large randomized trial with clinical outcomes (auto-provisional; risk of bias and consistency not yet assessed).
Assessment
Version 2 · curated · Sep 13, 2026

Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.

Oral semaglutide reduced major cardiovascular events by 14% over four years in 9,650 people with type 2 diabetes and vascular or kidney disease; kidney outcomes were not significantly improved. Same diabetes-population caveat as other outcome trials.

01Findings

What the study reported

Drugs
Semaglutide
Dose
oral, up to 14 mg daily
Route
oral
Treatment duration
mean 47.5 months
Comparator
placebo
Primary outcome
MACE (CV death, nonfatal MI, nonfatal stroke)
Effect
HR 0.86 (12.0% vs 13.8%); kidney composite not significantly different
95% confidence interval
0.77 to 0.96
P value
0.006
Follow-up
mean 47.5 months
Adverse events
Serious adverse events 47.9% vs 50.3%; GI disorders 5.0% vs 4.4%.
Limitations
Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.

Who was studied

Age min
50
Diabetes status
type 2 diabetes required
Cvd status
ASCVD and/or CKD required
Ckd status
chronic kidney disease present in population (see abstract)
Baseline condition
chronic kidney disease
Sample size
9650

Study quality details

Study design
Randomized controlled trial
Sample size
9650
Randomization
yes
Blinding
double-blind
Comparator
placebo
Follow up duration
50 years
Outcome type
hard
Replication
not assessed (auto)
Consistency with other evidence
not assessed (auto)
Population applicability
INDIRECT
Statistical precision
CI reported: 95% confidence interval, 0
Risk of bias
not assessed (auto)
Funding conflicts
yes
Peer review status
yes
02Funding

Funding and conflicts

Funding
Novo Nordisk
Industry funded
Yes
Manufacturer
Novo Nordisk
Sponsor role
Sponsor designed and analysed.
Author conflicts
Authors report Novo Nordisk relationships; sponsor co-authors.
Independent replication
unknown
Notes
Authors declare relationships with the drug's manufacturer: Novo Nordisk

Funding is shown on every study and never used to score it.

04Source

The source, as retrieved

Abstract

[BACKGROUND] The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed. [METHODS] In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome). [RESULTS] Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively. [CONCLUSIONS] Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).

Where this record came from

SourceRetrievedIdentifier
pubmedSep 13, 202640162642
first ingestion